Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression.

Saved in:
Bibliographic Details
Title: Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression.
Authors: Guo H; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China., Li Y; Department of Pharmacy, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China., Jin C; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China., Qi X; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China., Wang J; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China., Li B; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China., Wang C; Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China.
Source: International journal of molecular medicine [Int J Mol Med] 2026 Jun; Vol. 57 (6). Date of Electronic Publication: 2026 Apr 30.
Publication Type: Journal Article
Journal Info: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9810955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-244X (Electronic) Linking ISSN: 11073756 NLM ISO Abbreviation: Int J Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1791-244X
DOI:10.3892/ijmm.2026.5839